U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235683) titled 'Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients' on Nov. 13.
Brief Summary: The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
CMV
Lung Transplant Recipient
Intervention:
DRUG: Letermovir
Letermovir (480mg) will be given orally as a loading dose every 1...